90% Returns, 5:1 Stock Split: Midcap Pharma Stock Jumps 5% On First Buyback Announcement; BUY?

Aurobindo Pharma's shares surged to a new high of Rs 1,394, rallying by 5% on the Bombay Stock Exchange (BSE) during Monday's intra-day trade. This uptick followed the company's announcement of a crucial board meeting scheduled for Thursday, July 18, 2024, to discuss a proposal for the buyback of fully paid-up equity shares. By 11 am, the stock was trading over 3% higher at Rs 1,374 on the National Stock Exchange (NSE).

The recent rally saw Aurobindo Pharma surpass its previous peak of Rs 1,343.85, recorded on July 10. The Hyderabad-based pharmaceutical giant's decision to consider a share buyback has ignited investor enthusiasm, pushing the stock to new heights. This buyback could proceed through either the tender offer route or the open market route, as outlined by the company's announcement on Sunday.

This move marks Aurobindo Pharma's first foray into the buyback of equity shares. Previously, in 2011, Aurobindo Pharma had executed a stock split, reducing the face value of its shares from Rs 5 to Rs 1. Subsequently, in 2015, the company issued bonus shares in a 1:1 ratio, giving shareholders an additional share for each share they held. Since then, there have been no further bonus issues, although the company has distributed interim dividends, with the highest being Rs 4.5 per share in 2022.

Aurobindo Pharma's stock has shown strong performance in 2024, rallying 29% compared to the benchmark index's 11.5% rise. Over the past year, the stock has surged by 89%, significantly outpacing the BSE Sensex's 21% gain. Furthermore, the stock has been an outperformer over a 12-month period, rising 80%, compared to the 47% gain seen by the Nifty Pharma index.

A share buyback involves a company purchasing its outstanding shares, effectively reducing the number of shares available in the open market. This reduction can increase the value of the remaining shares by limiting supply, potentially offering a benefit to existing shareholders.

Aurobindo Pharma is renowned for its robust portfolio, primarily engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The anticipation of the upcoming board meeting has generated significant interest among investors, with many speculating on the potential impact of the buyback. If approved, the buyback could lead to a reduction in the total number of shares, thereby increasing the earnings per share (EPS) and potentially driving up the stock price further.

As the board meeting approaches, market watchers and investors will be observing the outcome. Aurobindo Pharma's strategic move to consider a buyback reflects its focus on enhancing shareholder value and could set a precedent for future corporate actions. With its shares already performing strongly, the buyback announcement has the potential to further boost investor confidence and drive the stock to new heights.